Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery A Randomized Controlled Trial
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00179906%3A_____%2F12%3A10125444" target="_blank" >RIV/00179906:_____/12:10125444 - isvavai.cz</a>
Výsledek na webu
<a href="http://dx.doi.org/10.1001/jama.2011.2002" target="_blank" >http://dx.doi.org/10.1001/jama.2011.2002</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1001/jama.2011.2002" target="_blank" >10.1001/jama.2011.2002</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery A Randomized Controlled Trial
Popis výsledku v původním jazyce
Abstract: Context Thienopyridines are among the most widely prescribed medications, but their use can be complicated by the unanticipated need for surgery. Despite increased risk of thrombosis, guidelines recommend discontinuing thienopyridines 5 to 7 days prior to surgery to minimize bleeding. Objective To evaluate the use of cangrelor, an intravenous, reversible P2Y(12) platelet inhibitor for bridging thienopyridine-treated patients to coronary artery bypass grafting (CABG) surgery. Design, Setting, and Patients Prospective, randomized, double-blind, placebo-controlled, multicenter trial, involving 210 patients with an acute coronary syndrome (ACS) or treated with a coronary stent and receiving a thienopyridine awaiting CABG surgery to receive eithercangrelor or placebo after an initial open-label, dose-finding phase (n=11) conducted between January 2009 and April 2011. Interventions Thienopyridines were stopped and patients were administered cangrelor or placebo for at least 48 hou
Název v anglickém jazyce
Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery A Randomized Controlled Trial
Popis výsledku anglicky
Abstract: Context Thienopyridines are among the most widely prescribed medications, but their use can be complicated by the unanticipated need for surgery. Despite increased risk of thrombosis, guidelines recommend discontinuing thienopyridines 5 to 7 days prior to surgery to minimize bleeding. Objective To evaluate the use of cangrelor, an intravenous, reversible P2Y(12) platelet inhibitor for bridging thienopyridine-treated patients to coronary artery bypass grafting (CABG) surgery. Design, Setting, and Patients Prospective, randomized, double-blind, placebo-controlled, multicenter trial, involving 210 patients with an acute coronary syndrome (ACS) or treated with a coronary stent and receiving a thienopyridine awaiting CABG surgery to receive eithercangrelor or placebo after an initial open-label, dose-finding phase (n=11) conducted between January 2009 and April 2011. Interventions Thienopyridines were stopped and patients were administered cangrelor or placebo for at least 48 hou
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FA - Kardiovaskulární nemoci včetně kardiochirurgie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Ostatní
Rok uplatnění
2012
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Journal of the American Medical Association
ISSN
0098-7484
e-ISSN
—
Svazek periodika
307
Číslo periodika v rámci svazku
3
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
10
Strana od-do
265-274
Kód UT WoS článku
000299161200022
EID výsledku v databázi Scopus
—